BR112018006393A2 - método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit - Google Patents

método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit

Info

Publication number
BR112018006393A2
BR112018006393A2 BR112018006393-2A BR112018006393A BR112018006393A2 BR 112018006393 A2 BR112018006393 A2 BR 112018006393A2 BR 112018006393 A BR112018006393 A BR 112018006393A BR 112018006393 A2 BR112018006393 A2 BR 112018006393A2
Authority
BR
Brazil
Prior art keywords
dlbcl
classifying
kit
computer readable
readable storage
Prior art date
Application number
BR112018006393-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Lafleur Bonnie
Liu Qian
W. Luecke John
C. Roche Patrick
Original Assignee
Htg Molecular Diagnostics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Htg Molecular Diagnostics, Inc. filed Critical Htg Molecular Diagnostics, Inc.
Publication of BR112018006393A2 publication Critical patent/BR112018006393A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018006393-2A 2015-09-29 2016-09-29 método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit BR112018006393A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562234491P 2015-09-29 2015-09-29
US62/234,491 2015-09-29
PCT/US2016/054501 WO2017059108A1 (en) 2015-09-29 2016-09-29 Methods for subtyping diffuse b-cell lymphoma (dlbcl)

Publications (1)

Publication Number Publication Date
BR112018006393A2 true BR112018006393A2 (pt) 2018-10-09

Family

ID=57138148

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006393-2A BR112018006393A2 (pt) 2015-09-29 2016-09-29 método para classificar um linfoma difuso de grande célula b (dlbcl), uma ou mais mídias de armazenamento legíveis por computador, sistema de computação adaptado e kit

Country Status (9)

Country Link
US (1) US11384399B2 (enExample)
EP (1) EP3356554B1 (enExample)
JP (1) JP6836586B2 (enExample)
CN (1) CN108368554B (enExample)
AU (1) AU2016331058B2 (enExample)
BR (1) BR112018006393A2 (enExample)
CA (1) CA3000405A1 (enExample)
ES (1) ES2765709T3 (enExample)
WO (1) WO2017059108A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696250B2 (en) * 2016-11-09 2023-07-04 Intel Corporation UE and devices for detach handling
WO2018231589A1 (en) 2017-06-14 2018-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for determining lymphoma type
WO2019036632A1 (en) * 2017-08-18 2019-02-21 Health Research, Inc. COMPOSITIONS AND METHODS FOR DETECTION OF CD30 MRM ISOFORMS FOR USE IN DRUG SELECTION
JP7357921B2 (ja) * 2017-09-29 2023-10-10 国立大学法人九州大学 びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CA3131874A1 (en) * 2019-03-28 2020-10-01 Philippe RUMINY Classification of b-cell non-hodgkin lymphomas
CN111621565B (zh) * 2020-05-07 2023-12-15 杭州可帮基因科技有限公司 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置
CN114469949A (zh) * 2020-10-27 2022-05-13 正大天晴药业集团股份有限公司 用于治疗弥漫大b细胞淋巴瘤的喹啉衍生物
CN117987359B (zh) * 2024-02-18 2024-08-30 中源协和生物细胞存储服务(天津)有限公司 用于从生物材料中分离细胞外囊泡的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
ES2155822T3 (es) 1990-12-06 2001-06-01 Affymetrix Inc Compuestos y su utilizacion en una estrategia de sintesis binaria.
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO1995030774A1 (en) 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
US5585069A (en) 1994-11-10 1996-12-17 David Sarnoff Research Center, Inc. Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5866330A (en) 1995-09-12 1999-02-02 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US5736330A (en) 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
US6449562B1 (en) 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
GB9624586D0 (en) 1996-11-27 1997-01-15 British Nuclear Fuels Plc Improvements in and relating to coils
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6238869B1 (en) 1997-12-19 2001-05-29 High Throughput Genomics, Inc. High throughput assay system
US6458533B1 (en) 1997-12-19 2002-10-01 High Throughput Genomics, Inc. High throughput assay system for monitoring ESTs
US20030096232A1 (en) 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US6232066B1 (en) 1997-12-19 2001-05-15 Neogen, Inc. High throughput assay system
AU2375600A (en) 1998-12-22 2000-07-12 Stephen Felder High throughput assay system using mass spectrometry
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
DE102005030336A1 (de) 2005-06-29 2007-01-04 Peri Gmbh Schienengeführtes Klettersystem
ATE525482T1 (de) 2005-12-23 2011-10-15 Nanostring Technologies Inc Nanoreporter und verfahren zu deren herstellung und verwendung
US20080268451A1 (en) 2007-03-30 2008-10-30 Bruce Seligmann Measurement of an insoluble analyte in a sample
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
WO2010117817A2 (en) * 2009-03-30 2010-10-14 Life Technologies Corporation Methods for generating target specific probes for solution based capture
AU2011224166B2 (en) 2010-03-12 2014-08-21 Celgene Corporation Methods for the treatment of non-Hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
AU2012251027B2 (en) 2011-05-04 2015-03-26 Htg Molecular Diagnostics, Inc. Quantitative nuclease protection Assay (qNPA) and sequencing (qNPS) improvements
EP3066215B1 (en) 2013-11-06 2019-04-24 The United States of America, represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling

Also Published As

Publication number Publication date
AU2016331058B2 (en) 2022-04-07
CN108368554A (zh) 2018-08-03
US20180340231A1 (en) 2018-11-29
JP2018536387A (ja) 2018-12-13
EP3356554B1 (en) 2019-10-30
US11384399B2 (en) 2022-07-12
WO2017059108A1 (en) 2017-04-06
ES2765709T3 (es) 2020-06-10
CA3000405A1 (en) 2017-04-06
EP3356554A1 (en) 2018-08-08
CN108368554B (zh) 2022-09-09
AU2016331058A1 (en) 2018-04-26
JP6836586B2 (ja) 2021-03-03

Similar Documents

Publication Publication Date Title
BR112017021986A2 (pt) sistema e método para extrair e compartilhar dados de usuário relacionados com aplicativo
BR112015025384A2 (pt) método
BR112015023883A2 (pt) método para avaliar planos de tratamento para a aplicação de radioterapia a um paciente; mídia não transitória legível por computador; e sistema para avaliar um plano de tratamento por radiação
CR20170104A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112016005634A2 (pt) categorizar solicitantes de seguros de vida para determinar produtos de seguros de vida adequados
MX2017014736A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112012016654A2 (pt) técnica de normalização de espaço-escala para detecção de recurso melhorada em mudanças de iluminação uniforme e não-uniforme.
MX2017008086A (es) Deteccion de objetos con red neuronal.
BR112017002834A2 (pt) transformações de fluxos de eventos
BR112017010388A2 (pt) escala dos agentes de assistente pessoal digital por meio de dispositivos
BR112015019570A8 (pt) método, sistema e meio de armazenamento por computador para manter compatibilidade de aplicativo com base em restrições de conjunto de atribuições
MX2018003938A (es) Sistemas y metodos de deteccion de cancer.
BR112015017767A2 (pt) sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo
BR112018015698A2 (pt) ?métodos diagnósticos e prognósticos para doenças cardiovasculares e eventos?
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112017008453A2 (pt) detecção automática de incompatibilidade de esquema
MY198081A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
BR112013028501A2 (pt) aparelho e método para processamento de dados seguro baseado em hardware utilizando regras de faixa de endereço de memória de armazenamento temporário
BR112019005025A8 (pt) Sistema e método para caracterizar um painel
BR112015031729A2 (pt) sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama
BR112013032640A2 (pt) carregar simultaneamente objetos multimídia e associar metadados com os objetos multimídia
MX387438B (es) Sistema y metodo de deteccion de hemolisis.
BR112013030271A2 (pt) método e aparelho para classificar múltiplos estados de dispositivo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements